by Katie Honeywood | Sep 1, 2026 | Uncategorized
At Osteosarcoma Now, our mission has always been to make trusted information about osteosarcoma accessible to everyone. Today, we are proud to relaunch our Clinical Trial Explorer (ONTEX) following a major redevelopment that transforms how clinical trial information...
by Katie Honeywood | Aug 4, 2026 | Uncategorized
There has been encouraging news from a Phase III clinical trial investigating a new treatment for people with relapsed or refractory osteosarcoma. What is the treatment? The treatment, called Ris-Rez (risvutatug rezetecan), is a type of targeted therapy known as an...
by Katie Honeywood | Jul 14, 2026 | Uncategorized
Osteosarcoma Now has been following the development of OST-HER2, one of the most advanced investigational therapies currently being developed specifically for osteosarcoma. Over the past three years, we have reported on the progression of the Phase 2b clinical trial,...
by Katie Honeywood | Jun 9, 2026 | Uncategorized
Tufts University Joins Global Effort to Find Better Treatments for Osteosarcoma Veterinary oncologists at Tufts University are part of the largest coordinated osteosarcoma research initiative ever launched, using clinical trials in pet dogs to generate insights that...
by Katie Honeywood | May 5, 2026 | Uncategorized
Research focuses on how osteosarcoma reaches the lungs and what may prevent it A research team at Oregon Health and Science University (OHSU) has been awarded $3.17 million from the National Institutes of Health to develop new laboratory models designed to better...
by Katie Honeywood | Apr 14, 2026 | Uncategorized
Treatment for osteosarcoma has remained largely unchanged for decades, particularly for patients with metastatic or relapsed disease. Targeted therapies are now being explored as a way to improve outcomes. One of these is cabozantinib, a drug currently being studied...
